8-K
filed May 29, 2026, 5:10 PM ET
ticker ATNM
CIK 0001388320
regulatory
confidence high
sentiment negative
materiality 0.75
Actinium receives NYSE American non-compliance notice for low stockholders' equity; must submit plan by June 26
Actinium Pharmaceuticals, Inc.
- Stockholders' equity $2.3M as of March 31, 2026, below NYSE American's $4M minimum; net losses in last 5 fiscal years.
- Must submit compliance plan by June 26, 2026; deadline to regain compliance by November 27, 2027.
- Company announced three ATNM-400 presentations at SNMMI 2026 (May 31-June 2) showing preclinical data in prostate cancer and NSCLC.
- If plan not accepted or compliance not regained, delisting proceedings will commence; no immediate effect on trading.
Machine-readable event card
- schema_version
- secwatch.filing_event.v1
- accession
- 0001213900-26-062935
- form_type
- 8-K
- ticker
- ATNM
- cik
- 0001388320
- company_name
- Actinium Pharmaceuticals, Inc.
- filed_at
- 2026-05-29T21:10:41+00:00
- discovered_at
- 2026-05-29T21:12:00.208107+00:00
- generated_at
- 2026-05-29T21:12:37.803596+00:00
- sec_items
- ["3.01", "7.01", "9.01"]
- event_type
- regulatory
- sentiment
- negative
- materiality_score
- 0.75
- calibrated_materiality_score
- 0.75
- confidence
- high
- secwatch_canonical_url
- https://secwatch.observer/filing/0001213900-26-062935
- json_url
- https://secwatch.observer/filing/0001213900-26-062935.json
- markdown_url
- https://secwatch.observer/filing/0001213900-26-062935.md
- text_url
- https://secwatch.observer/filing/0001213900-26-062935.txt
- edgar_index_url
- https://www.sec.gov/Archives/edgar/data/1388320/000121390026062935/0001213900-26-062935-index.htm
- edgar_primary_document_url
- https://www.sec.gov/Archives/edgar/data/1388320/000121390026062935/ea0292691-8k_actinium.htm
- generated_by_model
- deepseek-v4-flash:cloud@v2
- review_status
- machine_generated
- human_reviewed
- false
- corrected
- false
- correction_note
- null
- correction_timestamp
- null
- superseded_by
- null
Comparable filings
GENC
Gencor receives NYSE American delinquency notice for late Q2 2026 10-Q filing
GENCOR INDUSTRIES INC
June 1, 2026, 4:09 PM ET
regulatory
Items 3.01, 7.01, 9.01
same fact type: exchange_compliance_notice
same SEC item: 3.01, 7.01, 9.01
same event type: regulatory
similar materiality
This filing
May 27, 2026, Actinium Pharmaceuticals, Inc.
(the “Company”) received a notice (the “Notice”) from NYSE American LLC (“NYSE American”) indicating
that the Company is not in compliance with the continued listing standards set forth in Section 1003(a)(ii) of the NYSE American Company
Guide (the “Company Guide”), which requires a listed company to maintain stockholders’ equity of $4.0 million or more
if it has reported losses from continuing operations and/or net losses in three of its four most recent fiscal years. As of March 31,
2026, the Company reported stockholders’ equity of approximately
Comparable filing
May 19, 2026, Gencor Industries, Inc. (the “Company”) received a notice (the “Delinquency Notification”) from NYSE Regulation (the “NYSE”) indicating the Company was not in compliance with the NYSE American LLC (“NYSE American”) continued listing standards as a result of its failure to timely file its Quarterly Report on Form 10-Q for the period ended March 31, 2026 (the “Form 10-Q”) with the Securities and Exchange Commission (“SEC”) prior to May 18, 2026, the end of the extension period provided by Form 12b-25, and as a result was subject to the procedures set forth in Section 1007 of the NY
Filing page
SEC filing
CDT
CDT Equity receives Nasdaq deficiency letter for late Q1 10-Q filing; has until July 20 to submit plan
CDT Equity Inc.
May 28, 2026, 4:30 PM ET
regulatory
Items 3.01, 7.01, 9.01
same fact type: exchange_compliance_notice
same SEC item: 3.01, 7.01, 9.01
same event type: regulatory
similar materiality
This filing
May 27, 2026, Actinium Pharmaceuticals, Inc.
(the “Company”) received a notice (the “Notice”) from NYSE American LLC (“NYSE American”) indicating
that the Company is not in compliance with the continued listing standards set forth in Section 1003(a)(ii) of the NYSE American Company
Guide (the “Company Guide”), which requires a listed company to maintain stockholders’ equity of $4.0 million or more
if it has reported losses from continuing operations and/or net losses in three of its four most recent fiscal years. As of March 31,
2026, the Company reported stockholders’ equity of approximately
Comparable filing
May 21, 2026, CDT Equity Inc. (the “Company”) received a deficiency letter (the “Notice”) from the Nasdaq Listing
Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that it was not in compliance with
Nasdaq Listing Rule 5250(c)(1) (the “Periodic Filing Requirement”) because the Company did not file its Quarterly Report
on Form 10-Q for the three-month period ended March 31, 2026 (the “Form 10-Q”) in a timely manner, as required for continued
listing on The Nasdaq Capital Market. The Notice has no immediate effect on the listing or trading of the Company’s
Filing page
SEC filing
GWAV
Greenwave receives second Nasdaq delinquency notice for late Q1 2026 10-Q filing
Greenwave Technology Solutions, Inc.
May 27, 2026, 5:25 PM ET
regulatory
Items 3.01, 7.01, 9.01
same fact type: exchange_compliance_notice
same SEC item: 3.01, 7.01, 9.01
same event type: regulatory
similar materiality
This filing
May 27, 2026, Actinium Pharmaceuticals, Inc.
(the “Company”) received a notice (the “Notice”) from NYSE American LLC (“NYSE American”) indicating
that the Company is not in compliance with the continued listing standards set forth in Section 1003(a)(ii) of the NYSE American Company
Guide (the “Company Guide”), which requires a listed company to maintain stockholders’ equity of $4.0 million or more
if it has reported losses from continuing operations and/or net losses in three of its four most recent fiscal years. As of March 31,
2026, the Company reported stockholders’ equity of approximately
Comparable filing
May 21, 2026, the Company received an additional delinquency notification letter (the “Notice”) from Nasdaq due to the Company’s
failure to timely file its Quarterly Report on Form 10-Q for the fiscal quarter ended March
Filing page
SEC filing
CHAR
Charlton Aria receives Nasdaq delinquency notice for untimely Q1 10-Q filing
Charlton Aria Acquisition Corp
May 27, 2026, 4:41 PM ET
regulatory
Items 3.01, 7.01, 9.01
same fact type: exchange_compliance_notice
same SEC item: 3.01, 7.01, 9.01
same event type: regulatory
similar materiality
This filing
May 27, 2026, Actinium Pharmaceuticals, Inc.
(the “Company”) received a notice (the “Notice”) from NYSE American LLC (“NYSE American”) indicating
that the Company is not in compliance with the continued listing standards set forth in Section 1003(a)(ii) of the NYSE American Company
Guide (the “Company Guide”), which requires a listed company to maintain stockholders’ equity of $4.0 million or more
if it has reported losses from continuing operations and/or net losses in three of its four most recent fiscal years. As of March 31,
2026, the Company reported stockholders’ equity of approximately
Comparable filing
May 22, 2026, Charlton
Aria Acquisition Corporation (the “ Company ”) received a letter (the “ Notice ”) from the Listing Qualifications
Department of The Nasdaq Stock Market LLC (“ Nasdaq ”), notifying the Company that
Filing page
SEC filing
BRLS
Borealis Foods receives Nasdaq deficiency notice for delayed Q1 2026 10-Q; supplements prior 2025 10-K notice
Borealis Foods Inc.
May 27, 2026, 4:15 PM ET
regulatory
Items 3.01, 7.01, 9.01
same fact type: exchange_compliance_notice
same SEC item: 3.01, 7.01, 9.01
same event type: regulatory
similar materiality
This filing
May 27, 2026, Actinium Pharmaceuticals, Inc.
(the “Company”) received a notice (the “Notice”) from NYSE American LLC (“NYSE American”) indicating
that the Company is not in compliance with the continued listing standards set forth in Section 1003(a)(ii) of the NYSE American Company
Guide (the “Company Guide”), which requires a listed company to maintain stockholders’ equity of $4.0 million or more
if it has reported losses from continuing operations and/or net losses in three of its four most recent fiscal years. As of March 31,
2026, the Company reported stockholders’ equity of approximately
Comparable filing
May 21, 2026, a notice
(the “ Notice ”) from The Nasdaq Stock Market LLC (“ Nasdaq ”) notifying the Company that, because the
Company has not yet filed the Q12026 Form 10-Q, the Company no longer complies with Nasdaq Lis
Filing page
SEC filing
FSHP
Flag Ship Acquisition receives second Nasdaq deficiency notice for late Q1 10-Q filing
Flag Ship Acquisition Corp
May 27, 2026, 9:10 AM ET
regulatory
Items 3.01, 7.01, 9.01
same fact type: exchange_compliance_notice
same SEC item: 3.01, 7.01, 9.01
same event type: regulatory
similar materiality
This filing
May 27, 2026, Actinium Pharmaceuticals, Inc.
(the “Company”) received a notice (the “Notice”) from NYSE American LLC (“NYSE American”) indicating
that the Company is not in compliance with the continued listing standards set forth in Section 1003(a)(ii) of the NYSE American Company
Guide (the “Company Guide”), which requires a listed company to maintain stockholders’ equity of $4.0 million or more
if it has reported losses from continuing operations and/or net losses in three of its four most recent fiscal years. As of March 31,
2026, the Company reported stockholders’ equity of approximately
Comparable filing
May 21, 2026, Flag Ship Acquisition Corporation
(the “Company”) received an additional deficiency letter (the “Notice”) from the Nasdaq Listing Qualifications
Department of The Nasdaq Stock Market LLC (“Nasdaq”) as a res
Filing page
SEC filing
VSTD
Vestand receives Nasdaq delisting notice for late quarterly and annual filings
Vestand Inc.
May 26, 2026, 5:18 PM ET
regulatory
Items 3.01, 7.01, 9.01
same fact type: exchange_compliance_notice
same SEC item: 3.01, 7.01, 9.01
same event type: regulatory
similar materiality
This filing
May 27, 2026, Actinium Pharmaceuticals, Inc.
(the “Company”) received a notice (the “Notice”) from NYSE American LLC (“NYSE American”) indicating
that the Company is not in compliance with the continued listing standards set forth in Section 1003(a)(ii) of the NYSE American Company
Guide (the “Company Guide”), which requires a listed company to maintain stockholders’ equity of $4.0 million or more
if it has reported losses from continuing operations and/or net losses in three of its four most recent fiscal years. As of March 31,
2026, the Company reported stockholders’ equity of approximately
Comparable filing
May 19, 2026, the Company received a Staff Delisting Determination letter (the “Staff Determination”) from Nasdaq notifying
it that Nasdaq has initiated a process which could result in the delisting of the Company’s secu
Filing page
SEC filing
NVVE
Nuvve receives Nasdaq delisting notice for late Q1 10-Q filing; already under $1.00 bid price review
Nuvve Holding Corp.
May 22, 2026, 6:35 PM ET
regulatory
Items 3.01, 7.01, 9.01
same fact type: exchange_compliance_notice
same SEC item: 3.01, 7.01, 9.01
same event type: regulatory
similar materiality
This filing
May 27, 2026, Actinium Pharmaceuticals, Inc.
(the “Company”) received a notice (the “Notice”) from NYSE American LLC (“NYSE American”) indicating
that the Company is not in compliance with the continued listing standards set forth in Section 1003(a)(ii) of the NYSE American Company
Guide (the “Company Guide”), which requires a listed company to maintain stockholders’ equity of $4.0 million or more
if it has reported losses from continuing operations and/or net losses in three of its four most recent fiscal years. As of March 31,
2026, the Company reported stockholders’ equity of approximately
Comparable filing
May 22, 2026, Nuvve Holding Corp. (the “Company”) received written notice (the “Notice”) from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that, since the Company
Filing page
SEC filing
This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice.
See methodology for how this pipeline works.